Case number 2022-1194
H. Lundbeck A/S v. Lupin Ltd. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Dec 13, 2023 | 0 | H. LUNDBECK A/S v. LUPIN LTD. [OPINION] [precedential] (0) |
| Aug 4, 2023 | 93 | Response to notice of oral argument from Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals International AG. Service: 08/04/2023 by email. [940798] [22-1194] [Brianne Bharkhda] [Entered: 08/04/2023 02:26 PM] (1) |
| Aug 4, 2023 | 92 | Response to notice of oral argument from Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 08/04/2023 by email. [940730] [22-1194] [Deepro Mukerjee] [Entered: 08/04/2023 11:59 AM] (1) |
| Aug 1, 2023 | 91 | Response to notice of oral argument from Cross-Appellant Zydus Pharmaceuticals (USA) Inc.. Service: 08/01/2023 by email. [939958] [22-1194] [David Abramowitz] [Entered: 08/01/2023 05:33 PM] (2) |
| Jul 21, 2023 | 90 | NOTICE OF ORAL ARGUMENT. Panel: 2309F. Case scheduled September 8, 2023. Response to Notice of Oral Argument due: 08/04/2023. Please review the attached Notice. The response to notice of oral argument form can be found here. The Oral Argument Guide can be found here. Service as of this date by the Clerk of Court. [937737] [MJL] [Entered: 07/21/2023 04:09 PM] (2) |
| Jul 20, 2023 | 89 | Clerk's Note to the File: The conflict dates requested by Appellants (see Doc. No. [88]) are not accepted at this time. [937373] [MJL] [Entered: 07/20/2023 01:23 PM] (0) |
| Jul 18, 2023 | 88 | Notice from Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals International AG regarding conflicts with oral argument. Service: 07/18/2023 by email. [937014] [22-1194] [Brianne Bharkhda] [Entered: 07/18/2023 04:24 PM] (3) |
| Jan 24, 2023 | 85 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Cross-Appellants' responses to the notice to advise of scheduling conflicts ([81] and [82]) identify three arguing counsel. Pursuant to FCR 34(e)(2), a maximum of two counsel will be permitted to present argument for Cross-Appellants. No conflict dates are accepted at this time. CORRECTION: Either up to two counsel may re-file conflict notices for Cross-Appellants, or the parties must file a motion to waive the requirements of FCR 34(e)(2). If conflicts are re-filed, each planned arguing counsel must appear on their own conflict form. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [898988] [MJL] [Entered: 01/24/2023 10:33 AM] (0) |
| Jan 24, 2023 | 84 | This entry was made in error and has been removed from the docket. The conflict dates have been accepted. [898976]--[Edited 01/24/2023 by MJL to partially delete entry] [MJL] [Entered: 01/24/2023 10:18 AM] (0) |
| Jan 18, 2023 | 87 | 6 paper copies of Doc. No. [68], [53], [51] received from Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc.. [899105] [VDW] [Entered: 01/24/2023 01:31 PM] (0) |
| Jan 18, 2023 | 86 | 6 paper copies of Doc. No. [76], [65], [42] received from Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. [899035] [VDW] [Entered: 01/24/2023 11:30 AM] (0) |
| Jan 18, 2023 | 83 | 6 paper copies of Doc. No. [67] received from Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc.. [898565] [VDW] [Entered: 01/23/2023 10:06 AM] (0) |
| Jan 18, 2023 | 82 | Notice from Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. regarding conflicts with oral argument. Service: 01/18/2023 by email. [897848] [22-1194] [Laura Lydigsen] [Entered: 01/18/2023 07:44 PM] (6) |
| Jan 18, 2023 | 81 | Notice from Cross-Appellants Lupin Pharmaceuticals, Inc. and Lupin Ltd. regarding conflicts with oral argument. Service: 01/18/2023 by email. [897778] [22-1194] [Deepro Mukerjee] [Entered: 01/18/2023 04:12 PM] (5) |
| Jan 17, 2023 | 80 | RESPONSE of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc. to Doc No. [77]. Service: 01/17/2023 by email. [897493] [22-1194] [Brianne Bharkhda] [Entered: 01/17/2023 07:49 PM] (2) |
| Jan 11, 2023 | 79 | Notice to Advise of Scheduling Conflicts. Arguing counsel must advise of, and show good cause for, any scheduling conflicts during the upcoming court session months listed in the attached notice. The Response to Notice to Advise of Scheduling Conflicts can be found here. The Oral Argument Guide can be found here. [896292] [EKD] [Entered: 01/11/2023 01:52 PM] (1) |
| Jan 11, 2023 | 78 | Outstanding paper copies of all briefs and appendices must be submitted within five business days from the date of issuance of this notice. See Fed. Cir. R. 25(c)(3)(A). [896291] [EKD] [Entered: 01/11/2023 01:52 PM] (0) |
| Jan 6, 2023 | 77 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc.. Service: 01/06/2023 by email. [895396] [22-1194] [Laura Lydigsen] [Entered: 01/06/2023 06:52 PM] (24) |
| Dec 29, 2022 | 76 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL APPENDIX FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. and Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. Service: 12/29/2022 by email. [893713]--[Edited 01/11/2023 by EKD - compliance review complete] [George Pappas] [Entered: 12/29/2022 05:27 PM] (0) |
| Dec 29, 2022 | 75 | MODIFIED ENTRY:CORRECTED APPENDIX FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals U.S.A., Inc. and Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. Service: 12/29/2022 by email. [893709] --[Edited 01/11/2023 by EKD - compliance review complete] [George Pappas] [Entered: 12/29/2022 05:13 PM] (2048) |
| Dec 22, 2022 | 74 | NOTICE OF NON-COMPLIANCE: The submission of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc., Appendix [70], [71], is not in compliance with the rules of this court (see attached). Compliant documents due on 12/30/2022. Service as of this date by the Clerk of Court. [892381] [KMH] [Entered: 12/22/2022 10:36 AM] (1) |
| Dec 8, 2022 | 73 | Certificate of Compliance with Fed. Cir. R. 25.1(c)(2) for Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/08/2022 by email. [889501] [22-1194] [George Pappas] [Entered: 12/08/2022 05:05 PM] (6) |
| Dec 8, 2022 | 72 | Joint Statement of Compliance with Fed. Cir. R. 33 for Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/08/2022 by email. [889500] [22-1194] [George Pappas] [Entered: 12/08/2022 04:52 PM] (8) |
| Dec 8, 2022 | 71 | CONFIDENTIAL APPENDIX FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/08/2022 by email. [889498] [22-1194] This document is non-compliant. See Doc No. [74] [George Pappas] [Entered: 12/08/2022 04:47 PM] (0) |
| Dec 8, 2022 | 70 | APPENDIX FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/08/2022 by email. [889492] [22-1194] This document is non-compliant. See Doc No. [74] [George Pappas] [Entered: 12/08/2022 04:40 PM] (2048) |
| Nov 22, 2022 | 69 | **TEXT ONLY** ORDER granting motion to extend time to file appendix [66] filed by Appellants Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG and H. Lundbeck A/S. The appendix is due 12/08/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [885725] [KMH] [Entered: 11/22/2022 08:31 AM] (0) |
| Nov 21, 2022 | 68 | MODIFIED ENTRY: REPLY BRIEF FILED by Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC, and Zydus Pharmaceuticals (USA) Inc.. Service: 11/21/2022 by email. [885699] --[Edited 11/30/2022 by CAB - compliance review complete] [Laura Lydigsen] [Entered: 11/21/2022 08:39 PM] (32) |
| Nov 21, 2022 | 67 | MODIFIED ENTRY: REPLY BRIEF FILED by Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 11/21/2022 by email. [885664] --[Edited 11/30/2022 by CAB - compliance review complete] [Deepro Mukerjee] [Entered: 11/21/2022 05:19 PM] (27) |
| Nov 17, 2022 | 66 | MOTION of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc. to extend the time to 12/08/2022 to file the appendix. Service: 11/17/2022 by email. [884659] [22-1194] [George Pappas] [Entered: 11/17/2022 11:00 AM] (10) |
| Oct 3, 2022 | 65 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL REPLY BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 10/03/2022 by email. [875439]--[Edited 10/11/2022 by KMH - compliance review complete] [Brianne Bharkhda] [Entered: 10/03/2022 03:24 PM] (0) |
| Sep 30, 2022 | 64 | CORRECTED REPLY BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/16/2022 by email. This document has been accepted. See Order [63] [875010] [KMH] [Entered: 09/30/2022 11:02 AM] (90) |
| Sep 30, 2022 | 63 | ORDER granting motion [60] to the extent that ECF No. 60-2 is accepted for filing as appellants' corrected non-confidential response and reply brief. Within five days of the date of filing of this order, appellants are directed to refile the corrected confidential response and reply brief with either: (1) a corrected Certificate of Service rectifying the deficiency noted in the order; or (2) a cover letter and pertinent protective order pursuant to Federal Circuit Rule 25.1(a)(2) indicating which parties or counsel are not authorized access. Cross-appellants' motion [62] is granted to the extent that their reply brief is due no later than November 21, 2022. Service as of this date by the Clerk of Court. [874989] [NL] [Entered: 09/30/2022 10:25 AM] (2) |
| Sep 20, 2022 | 62 | MOTION of Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. to extend the time to 11/21/2022 to file brief. Service: 09/20/2022 by email. [872910] [22-1194] [Laura Lydigsen] [Entered: 09/20/2022 08:03 PM] (26) |
| Sep 16, 2022 | 61 | Confidential Motion for Extension of Time Attachment: Corrected Confidential Response and Reply Brief filed by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc. corresponding to Doc. No. [60]. Service: 09/16/2022 by email. [872375] [22-1194] [Brianne Bharkhda] [Entered: 09/16/2022 07:26 PM] (0) |
| Sep 16, 2022 | 60 | MOTION of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc. to extend the time to 09/12/2022 to file brief. Service: 09/16/2022 by email. [872374] [22-1194] [Brianne Bharkhda] [Entered: 09/16/2022 07:19 PM] (112) |
| Sep 14, 2022 | 59 | NOTICE OF NON-COMPLIANCE: The submission of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc., Response and Reply Brief [56], [57], [58], is not in compliance with the rules of this court (see attached). Compliant document due on 09/21/2022. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [871761] [KMH] [Entered: 09/14/2022 03:47 PM] (2) |
| Sep 10, 2022 | 58 | REPLY BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/09/2022 by email. [871034] [22-1194] This document is non-compliant. See Doc No. [59] [Brianne Bharkhda] [Entered: 09/10/2022 12:20 AM] (62) |
| Sep 10, 2022 | 57 | REPLY BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/09/2022 by email. [871033] [22-1194] This document is non-compliant. See Doc No. [59] [Brianne Bharkhda] [Entered: 09/10/2022 12:13 AM] (40) |
| Sep 10, 2022 | 56 | CONFIDENTIAL REPLY BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 09/09/2022 by email. [871032] [22-1194] This document is non-compliant. See Doc No. [59] [Brianne Bharkhda] [Entered: 09/10/2022 12:12 AM] (0) |
| Jul 18, 2022 | 55 | ORDER granting motion to extend time to file brief [54] filed by Appellants. The response and reply brief is due no later than September 9, 2022. Service as of this date by the Clerk of Court. [861629] [LMS] [Entered: 07/18/2022 04:15 PM] (2) |
| Jul 18, 2022 | 54 | MOTION of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc. to extend the time to 09/09/2022 to file brief. Service: 07/18/2022 by email. [861492] [22-1194] [Brianne Bharkhda] [Entered: 07/18/2022 11:00 AM] (15) |
| Jul 1, 2022 | 53 | MODIFIED ENTRY: CORRECTED RESPONSE BRIEF FILED by Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc.. Service: 07/01/2022 by email. [858785] --[Edited 07/01/2022 by JCW - compliance review complete] [Laura Lydigsen] [Entered: 07/01/2022 01:32 PM] (89) |
| Jun 27, 2022 | 52 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc., Response Brief [47], is not in compliance with the rules of this court (see attached). Compliant document due on 07/05/2022. Service as of this date by the Clerk of Court. [857479] [JCW] [Entered: 06/27/2022 10:09 AM] (1) |
| Jun 17, 2022 | 51 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL RESPONSE BRIEF FILED by Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/17/2022 by email. [856325]--[Edited 06/21/2022 by JCW - compliance review complete] [Deepro Mukerjee] [Entered: 06/17/2022 04:55 PM] (0) |
| Jun 17, 2022 | 50 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc., Confidential Response Brief [48], is not in compliance with the rules of this court (see attached). Compliant document due on 06/27/2022. Service as of this date by the Clerk of Court. [856083] [JCW] [Entered: 06/17/2022 09:00 AM] (1) |
| Jun 16, 2022 | 48 | CONFIDENTIAL RESPONSE BRIEF FILED by Cross-Appellants Lupin Pharmaceuticals, Inc. and Lupin Ltd.. Service: 06/16/2022 by email. [856065] [22-1194] This document is non-compliant. See Doc No.[50] [Deepro Mukerjee] [Entered: 06/16/2022 09:24 PM] (0) |
| Jun 16, 2022 | 47 | RESPONSE BRIEF FILED by Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc.. Service: 06/16/2022 by email. [856064] This document is non-compliant. See Doc No.[52] [Laura Lydigsen] [Entered: 06/16/2022 07:52 PM] (88) |
| Jun 16, 2022 | 49 | MODIFIED ENTRY: RESPONSE BRIEF FILED by Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 06/16/2022 by email. Unless ordered otherwise, any responsive deadline runs from the date of service of this brief. See Fed. Cir. R. 31. [856066] --[Edited 06/27/2022 by JCW - compliance review complete] [Deepro Mukerjee] [Entered: 06/16/2022 09:27 PM] (36) |
| May 26, 2022 | 46 | Entry of appearance for Laura A. Lydigsen; Mark H. Remus; Mary LaFleur as counsel for Cross-Appellants Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.. Service: 05/26/2022 by email. [852167] [22-1194] [Laura Lydigsen] [Entered: 05/26/2022 01:02 PM] (2) |
| May 26, 2022 | 45 | Entry of appearance for Laura Lydigsen; Mark Remus; Mary LaFleur as counsel for Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 05/26/2022 by email. [852165] [22-1194] [Laura Lydigsen] [Entered: 05/26/2022 12:59 PM] (1) |
| Apr 22, 2022 | 44 | **TEXT ONLY** ORDER granting motion to extend time to file brief [43] filed by Cross-Appellants Lupin Pharmaceuticals, Inc., Sandoz Inc., Lupin Ltd., Sigmapharm Laboratories, LLC, Alembic Pharmaceuticals Limited, Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Cadila Healthcare Ltd., Zydus Pharmaceuticals (USA) Inc., Lek Pharmaceuticals, d.d., Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.. The response brief is due 06/16/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [844951] [JCW] [Entered: 04/22/2022 01:55 PM] (0) |
| Apr 22, 2022 | 43 | MOTION of Cross-Appellants Alembic Global Holding S.A., Alembic Pharmaceuticals Inc., Alembic Pharmaceuticals Limited, Cadila Healthcare Ltd., Lek Pharmaceuticals, d.d., Lupin Ltd., Lupin Pharmaceuticals, Inc., Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Sandoz Inc., Sigmapharm Laboratories, LLC and Zydus Pharmaceuticals (USA) Inc. to extend the time to 06/16/2022 to file brief. Service: 04/22/2022 by email. [844935] [22-1194] [David Abramowitz] [Entered: 04/22/2022 01:34 PM] (27) |
| Mar 23, 2022 | 42 | MODIFIED ENTRY: CORRECTED CONFIDENTIAL OPENING BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/23/2022 by email. [838589]--[Edited 03/23/2022 by JCW - compliance review complete] [George Pappas] [Entered: 03/23/2022 02:12 PM] (0) |
| Mar 23, 2022 | 41 | MODIFIED ENTRY: CORRECTED OPENING BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/23/2022 by email. [838586] --[Edited 03/23/2022 by JCW - compliance review complete] [George Pappas] [Entered: 03/23/2022 02:05 PM] (578) |
| Mar 22, 2022 | 40 | NOTICE OF NON-COMPLIANCE: The submission of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc., Opening Brief [39], [38], is not in compliance with the rules of this court (see attached). Compliant document due on 03/29/2022. Unless ordered otherwise, the deadline for any responsive filing runs from service of the original version. Service as of this date by the Clerk of Court. [838194] [JCW] [Entered: 03/22/2022 09:23 AM] (1) |
| Mar 21, 2022 | 39 | CONFIDENTIAL OPENING BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/21/2022 by email. [838136] [22-1194] This document is non-compliant. See Doc No.[40] [George Pappas] [Entered: 03/21/2022 10:45 PM] (0) |
| Mar 21, 2022 | 38 | OPENING BRIEF FILED by Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 03/21/2022 by email. [838134] [22-1194] This document is non-compliant. See Doc No.[40] [George Pappas] [Entered: 03/21/2022 10:34 PM] (578) |
| Mar 8, 2022 | 37 | Amended Certificate of Interest for Cross-Appellants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd.. Service: 03/08/2022 by email. [835497] [22-1194] [David Abramowitz] [Entered: 03/08/2022 03:48 PM] (3) |
| Jan 20, 2022 | 36 | **TEXT ONLY** ORDER granting motion to extend time to file brief [35] filed by Appellants Takeda Pharmaceuticals America, Inc., Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals International AG and H. Lundbeck A/S. The opening brief is due 03/21/2022. Service as of this date by the Clerk of Court. This order has been issued without an attached document and is official and binding. [825561] [JCW] [Entered: 01/20/2022 08:52 AM] (0) |
| Jan 19, 2022 | 35 | MOTION of Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc. and Takeda Pharmaceuticals International AG to extend the time to 03/21/2022 to file brief. Service: 01/19/2022 by email. [825539] [22-1194] [George Pappas] [Entered: 01/19/2022 06:18 PM] (15) |
| Jan 10, 2022 | 34 | ORDER granting motion to modify the official caption [33] filed by Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d. The revised official caption is reflected in the order. Service as of this date by the Clerk of Court. [823585] [NL] [Entered: 01/10/2022 03:15 PM] (2) |
| Jan 7, 2022 | 33 | MOTION of Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d. to modify the official caption. Service: 01/07/2022 by email. [823243] [22-1194] [Laura Lydigsen] [Entered: 01/07/2022 10:44 AM] (14) |
| Jan 7, 2022 | 32 | Notice to Appellee Sandoz AG: The record of this case indicates that no Entry of Appearance under FCR 47.3(b), Certificate of Interest under FCR 47.4, and/or Docketing Statement under FCR 33.1(a) has been filed. Failure to file required documents may result in dismissal or other action as deemed appropriate by the court. See FCR 25(h). Service as of this date by the Clerk of Court. [823219] [JCW] [Entered: 01/07/2022 09:24 AM] (0) |
| Dec 30, 2021 | 31 | Corrected Entry of appearance for DON J. MIZERK; MARC R. WEZOWSKI; THOMAS P. HENEGHAN; PHILIP D. SEGREST, JR.; MATTHEW KAMPS as counsel for Cross-Appellant Sigmapharm Laboratories, LLC N/A. Service: 12/30/2021 by email. [821922] [22-1194] [Donald Mizerk] [Entered: 12/30/2021 09:26 AM] (2) |
| Dec 21, 2021 | 30 | Corrected Entry of appearance for Deepro R. Mukerjee; Lance A. Soderstrom; Joseph M. Janusz; Jitendra Malik as counsel for Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 12/21/2021 by email. [820235] [22-1194] [Deepro Mukerjee] [Entered: 12/21/2021 12:41 PM] (2) |
| Dec 21, 2021 | 29 | Amended Certificate of Interest for Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 12/21/2021 by email. [820233] [22-1194] [Deepro Mukerjee] [Entered: 12/21/2021 12:37 PM] (3) |
| Dec 14, 2021 | 28 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc., Entry of Appearance [23], is not in compliance with the rules of this court (see attached). Compliant document due on 12/21/2021. Service as of this date by the Clerk of Court. [818447] [JCW] [Entered: 12/14/2021 10:56 AM] (1) |
| Dec 13, 2021 | 27 | Entry of appearance for George F. Pappas; Einar Stole; Brianne Bharkhda; Kurt Calia as counsel for Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/13/2021 by email. [818323] [22-1194] [George Pappas] [Entered: 12/13/2021 06:02 PM] (2) |
| Dec 13, 2021 | 26 | Certificate of Interest for Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/13/2021 by email. [818322] [22-1194] [George Pappas] [Entered: 12/13/2021 05:59 PM] (4) |
| Dec 13, 2021 | 25 | Docketing Statement for the Appellants H. Lundbeck A/S, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals International AG and Takeda Pharmaceuticals U.S.A., Inc.. Service: 12/13/2021 by email. [818321] [22-1194] [George Pappas] [Entered: 12/13/2021 05:56 PM] (2) |
| Dec 13, 2021 | 24 | Docketing Statement for the Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 12/13/2021 by email. [818205] [22-1194] [Laura Lydigsen] [Entered: 12/13/2021 04:01 PM] (3) |
| Dec 13, 2021 | 23 | Entry of appearance for Deepro R. Mukerjee; Lance A. Soderstrom; Joseph M. Janusz; Jitendra Malik; Brian Sodikoff as counsel for Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 12/13/2021 by email. [818202] [22-1194] [Deepro Mukerjee] [Entered: 12/13/2021 04:00 PM] (2) |
| Dec 13, 2021 | 22 | Certificate of Interest for Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 12/13/2021 by email. [818199] [22-1194] [Laura Lydigsen] [Entered: 12/13/2021 03:58 PM] (3) |
| Dec 13, 2021 | 21 | Certificate of Interest for Cross-Appellants Lupin Pharmaceuticals, Inc. and Lupin Ltd.. Service: 12/13/2021 by email. [818197] [22-1194] [Deepro Mukerjee] [Entered: 12/13/2021 03:57 PM] (3) |
| Dec 13, 2021 | 20 | Docketing Statement for the Cross-Appellants Lupin Ltd. and Lupin Pharmaceuticals, Inc.. Service: 12/13/2021 by email. [818195] [22-1194] [Deepro Mukerjee] [Entered: 12/13/2021 03:56 PM] (2) |
| Dec 13, 2021 | 19 | Entry of appearance for Laura A. Lydigsen; Mark H. Remus as counsel for Cross-Appellants Sandoz Inc. and Lek Pharmaceuticals, d.d.. Service: 12/13/2021 by email. [818192] [22-1194] [Laura Lydigsen] [Entered: 12/13/2021 03:53 PM] (1) |
| Dec 13, 2021 | 18 | Docketing Statement for the Cross-Appellants Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.. Service: 12/13/2021 by email. [818121] [22-1194] [Christopher Sorenson] [Entered: 12/13/2021 01:24 PM] (2) |
| Dec 13, 2021 | 17 | NOTICE OF NON-COMPLIANCE: The submission of Cross-Appellant Sigmapharm Laboratories, LLC, Entry of Appearance [14], is not in compliance with the rules of this court (see attached). Compliant document due on 12/20/2021. Service as of this date by the Clerk of Court. [818042] [JCW] [Entered: 12/13/2021 11:26 AM] (1) |
| Dec 13, 2021 | 16 | Docketing Statement for the Cross-Appellant Sigmapharm Laboratories, LLC. Service: 12/13/2021 by email. [818035] [22-1194] [Donald Mizerk] [Entered: 12/13/2021 11:06 AM] (2) |
| Dec 13, 2021 | 15 | Certificate of Interest for Cross-Appellant Sigmapharm Laboratories, LLC. Service: 12/13/2021 by email. [818034] [22-1194] [Donald Mizerk] [Entered: 12/13/2021 11:05 AM] (3) |
| Dec 13, 2021 | 14 | Entry of appearance for Don J. Mizerk; Marc R. Wezowski; Thomas P. Heneghan; Philip D. Segrest, Jr.; Matthew Kamps as counsel for Cross-Appellant Sigmapharm Laboratories, LLC. Service: 12/13/2021 by email. [818033] [22-1194] This document is non-compliant. See Doc No.[17] [Donald Mizerk] [Entered: 12/13/2021 11:03 AM] (2) |
| Dec 13, 2021 | 13 | Docketing Statement for the Cross-Appellants Cadila Healthcare Ltd. and Zydus Pharmaceuticals (USA) Inc.. Service: 12/13/2021 by email. [818004] [22-1194] [David Abramowitz] [Entered: 12/13/2021 10:07 AM] (2) |
| Dec 10, 2021 | 12 | Official caption revised to reflect cross-appeal with 22-1246. (see attached). Service as of this date by the Clerk of Court. [817770] [JCW] [Entered: 12/10/2021 01:46 PM] (2) |
| Dec 10, 2021 | 11 | Note to File: The following cases are consolidated: 22-1194 Lead with 22-1246 Cross-Appeal. The parties must file all documents in the lead appeal only. [817768] [22-1194, 22-1246] [JCW] [Entered: 12/10/2021 01:44 PM] (0) |
| Dec 10, 2021 | 10 | Certificate of Interest for Appellees Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.. Service: 12/10/2021 by email. [817743] [22-1194] [Christopher Sorenson] [Entered: 12/10/2021 12:40 PM] (4) |
| Dec 10, 2021 | 9 | Entry of appearance for Christopher J. Sorenson as counsel for Appellees Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd.. Service: 12/10/2021 by email. [817742] [22-1194] [Christopher Sorenson] [Entered: 12/10/2021 12:37 PM] (1) |
| Dec 9, 2021 | 8 | Docketing Statement for the Appellees Alembic Pharmaceuticals Limited, Alembic Global Holding S.A. and Alembic Pharmaceuticals Inc.. Service: 12/09/2021 by email. [817606] [22-1194] [Bradley Graveline] [Entered: 12/09/2021 08:14 PM] (2) |
| Dec 9, 2021 | 7 | Certificate of Interest for Appellees Alembic Pharmaceuticals Limited, Alembic Global Holding S.A. and Alembic Pharmaceuticals Inc.. Service: 12/09/2021 by email. [817605] [22-1194] [Bradley Graveline] [Entered: 12/09/2021 07:58 PM] (3) |
| Dec 9, 2021 | 6 | Entry of appearance for Bradley C. Graveline; Todd E. Lundell; Laura Burson, Jesse A. Salen as counsel for Appellees Alembic Pharmaceuticals Limited, Alembic Global Holding S.A. and Alembic Pharmaceuticals Inc.. Service: 12/09/2021 by email. [817604] [22-1194] [Bradley Graveline] [Entered: 12/09/2021 07:52 PM] (2) |
| Dec 9, 2021 | 5 | Certificate of Interest for Appellees Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd.. Service: 12/09/2021 by email. [817434] [22-1194] [David Abramowitz] [Entered: 12/09/2021 11:20 AM] (4) |
| Dec 9, 2021 | 4 | Entry of appearance for Michael J. Gaertner; David B. Abramowitz; Hugh S. Balsam; Carolyn A. Blessing; Timothy F. Peterson; Jonathan B. Turpin; August M. Melcher as counsel for. Service: 12/09/2021 by email. [817433] [22-1194] [David Abramowitz] [Entered: 12/09/2021 11:19 AM] (2) |
| Dec 1, 2021 | 3 | Official caption revised to reflect cross-appeal with 22-1208. (see attached). Service as of this date by the Clerk of Court. [815567] [JCW] [Entered: 12/01/2021 11:24 AM] (2) |
| Dec 1, 2021 | 2 | Note to File: The following cases are consolidated: 22-1194 Lead with 22-1208 Cross-Appeal. The parties must file all documents in the lead appeal only. [815566] [22-1194, 22-1208] [JCW] [Entered: 12/01/2021 11:23 AM] (0) |
| Nov 29, 2021 | 1 | Appeal docketed. Received: 11/24/2021. [815036]Entry of Appearance is due on 12/13/2021. Certificate of Interest is due on 12/13/2021. Docketing Statement is due on 12/13/2021. Appellants' brief is due on 01/28/2022. [JCW] [Entered: 11/29/2021 01:45 PM] (213) |
